Syncom Formulations (India) Limited (SYNCOMF.NS)
INR 16.76
(2.63%)
INR 16.76
(2.63%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 345.63 Million INR | -38.04% |
| 2022 | 674.67 Million INR | 25.64% |
| 2021 | 536.99 Million INR | 43.87% |
| 2020 | 373.24 Million INR | 23.67% |
| 2019 | 301.81 Million INR | -8.65% |
| 2018 | 330.38 Million INR | 1.96% |
| 2017 | 324.03 Million INR | -17.01% |
| 2016 | 390.43 Million INR | 14.33% |
| 2015 | 341.5 Million INR | -19.97% |
| 2014 | 426.72 Million INR | 28.85% |
| 2013 | 331.19 Million INR | 11.77% |
| 2012 | 296.31 Million INR | 141.8% |
| 2011 | 122.54 Million INR | 512.4% |
| 2010 | 20 Million INR | 9.49% |
| 2009 | 18.27 Million INR | 182.48% |
| 2008 | 6.46 Million INR | -11.23% |
| 2007 | 7.28 Million INR | 134.03% |
| 2006 | -21.41 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 126.38 Million INR | -8.14% |
| 2023 Q1 | 189.26 Million INR | 0.58% |
| 2023 FY | 418.01 Million INR | -38.04% |
| 2023 Q4 | 137.58 Million INR | 61.53% |
| 2023 Q3 | 85.17 Million INR | -55.65% |
| 2023 Q2 | 192.07 Million INR | 1.48% |
| 2022 Q3 | 179.06 Million INR | 18.96% |
| 2022 FY | 674.67 Million INR | 25.64% |
| 2022 Q1 | 156.84 Million INR | 51.63% |
| 2022 Q2 | 150.52 Million INR | -4.03% |
| 2022 Q4 | 188.17 Million INR | 5.09% |
| 2021 Q4 | 103.44 Million INR | -32.3% |
| 2021 Q1 | 122.07 Million INR | 92.4% |
| 2021 Q2 | 158.67 Million INR | 29.98% |
| 2021 FY | 536.99 Million INR | 43.87% |
| 2021 Q3 | 152.79 Million INR | -3.71% |
| 2020 Q2 | 99.06 Million INR | 29.56% |
| 2020 FY | 373.24 Million INR | 23.67% |
| 2020 Q4 | 63.44 Million INR | -52.75% |
| 2020 Q3 | 134.27 Million INR | 35.55% |
| 2020 Q1 | 76.46 Million INR | 278.38% |
| 2019 FY | 301.81 Million INR | -8.65% |
| 2019 Q4 | -42.86 Million INR | -140.31% |
| 2019 Q3 | 106.32 Million INR | -15.68% |
| 2019 Q2 | 126.09 Million INR | 12.32% |
| 2019 Q1 | 112.25 Million INR | 2322.95% |
| 2018 FY | 330.38 Million INR | 1.96% |
| 2018 Q4 | 4.63 Million INR | -95.89% |
| 2018 Q3 | 112.8 Million INR | -6.02% |
| 2018 Q2 | 120.03 Million INR | 29.18% |
| 2018 Q1 | 92.91 Million INR | -8.81% |
| 2017 Q1 | 98.35 Million INR | -22.47% |
| 2017 FY | 324.03 Million INR | -17.01% |
| 2017 Q4 | 101.89 Million INR | -5.19% |
| 2017 Q3 | 107.47 Million INR | -2.0% |
| 2017 Q2 | 109.66 Million INR | 11.5% |
| 2016 FY | 390.43 Million INR | 14.33% |
| 2016 Q4 | 126.86 Million INR | 0.0% |
| 2016 Q1 | 97.27 Million INR | 35.1% |
| 2015 Q4 | 72 Million INR | -8.21% |
| 2015 Q3 | 78.43 Million INR | -17.03% |
| 2015 Q2 | 94.53 Million INR | -2.07% |
| 2015 FY | 341.5 Million INR | -19.97% |
| 2015 Q1 | 96.53 Million INR | -23.85% |
| 2014 Q4 | 126.76 Million INR | 23.66% |
| 2014 Q3 | 102.5 Million INR | -5.04% |
| 2014 Q2 | 107.94 Million INR | 20.58% |
| 2014 Q1 | 89.51 Million INR | 43.13% |
| 2014 FY | 426.72 Million INR | 28.85% |
| 2013 Q1 | 82.55 Million INR | -62.03% |
| 2013 Q4 | 62.54 Million INR | -29.42% |
| 2013 Q3 | 88.6 Million INR | -9.11% |
| 2013 Q2 | 97.48 Million INR | 18.09% |
| 2013 FY | 331.19 Million INR | 11.77% |
| 2012 Q3 | 24.77 Million INR | -17.1% |
| 2012 Q4 | 217.38 Million INR | 777.59% |
| 2012 FY | 296.31 Million INR | 141.8% |
| 2012 Q1 | 24.27 Million INR | 0.0% |
| 2012 Q2 | 29.87 Million INR | 23.1% |
| 2011 FY | 122.54 Million INR | 512.4% |
| 2010 FY | 20 Million INR | 9.49% |
| 2009 FY | 18.27 Million INR | 182.48% |
| 2008 FY | 6.46 Million INR | -11.23% |
| 2007 FY | 7.28 Million INR | 134.03% |
| 2006 FY | -21.41 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 97.822% |
| Hester Biosciences Limited | 908.84 Million INR | 61.97% |
| Aarti Drugs Limited | 1.16 Billion INR | 70.395% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 88.758% |
| Albert David Limited | 1.02 Billion INR | 66.317% |
| Alembic Limited | 872.45 Million INR | 60.384% |
| Alkem Laboratories Limited | 32.83 Billion INR | 98.947% |
| Bafna Pharmaceuticals Limited | 455.58 Million INR | 24.134% |
| Bajaj HealthCare Limited | 985.34 Million INR | 64.923% |
| Biofil Chemicals and Pharmaceuticals Limited | 6.82 Million INR | -4967.933% |
| Brooks Laboratories Limited | 51.18 Million INR | -575.328% |
| Eris Lifesciences Limited | 4.94 Billion INR | 93.008% |
| FDC Limited | 3.49 Billion INR | 90.124% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 97.031% |
| Gufic Biosciences Limited | 1.18 Billion INR | 70.872% |
| Hikal Limited | 4.46 Billion INR | 92.257% |
| Ind-Swift Limited | 946.56 Million INR | 63.486% |
| Innova Captab Limited | 931.03 Million INR | 62.876% |
| IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | 84.297% |
| Jagsonpal Pharmaceuticals Limited | 438.55 Million INR | 21.187% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 97.609% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | 67.824% |
| Lupin Limited | 125.09 Billion INR | 99.724% |
| Mangalam Drugs & Organics Limited | 162.22 Million INR | -113.054% |
| Medico Remedies Limited | 59.67 Million INR | -479.192% |
| Morepen Laboratories Limited | 1.98 Billion INR | 82.609% |
| Nectar Lifesciences Limited | 932.7 Million INR | 62.943% |
| Orchid Pharma Limited | 800.77 Million INR | 56.837% |
| Procter & Gamble Health Limited | 2.99 Billion INR | 88.461% |
| RPG Life Sciences Limited | 1.63 Billion INR | 78.867% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | 16.195% |
| Sigachi Industries Limited | 579.88 Million INR | 40.396% |
| Solara Active Pharma Sciences Limited | 2.55 Billion INR | 86.468% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | 75.361% |
| Themis Medicare Limited | 1.12 Billion INR | 69.299% |
| Unichem Laboratories Limited | 6.72 Billion INR | 94.861% |
| Vaishali Pharma Limited | 84.02 Million INR | -311.326% |
| Wanbury Limited | 978.96 Million INR | 64.694% |
| Windlas Biotech Limited | 1 Billion INR | 65.66% |
| ZIM Laboratories Limited | 1.01 Billion INR | 65.882% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | 83.729% |
| Ipca Laboratories Limited | 18.98 Billion INR | 98.18% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.776% |
| Venus Remedies Limited | 1.91 Billion INR | 81.963% |
| Sakar Healthcare Limited | 204.07 Million INR | -69.362% |
| Aurobindo Pharma Limited | 55.65 Billion INR | 99.379% |
| Divi's Laboratories Limited | 14.17 Billion INR | 97.561% |
| AstraZeneca Pharma India Limited | 2.47 Billion INR | 86.027% |
| Mankind Pharma Limited | 29.27 Billion INR | 98.819% |
| Sequent Scientific Limited | 2.9 Billion INR | 88.089% |
| Laurus Labs Limited | 11.9 Billion INR | 97.098% |
| Neuland Laboratories Limited | 2.92 Billion INR | 88.203% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 97.663% |
| Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 99.264% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 99.724% |
| Amrutanjan Health Care Limited | 2.09 Billion INR | 83.494% |
| Wockhardt Limited | 8.48 Billion INR | 95.924% |
| Bal Pharma Limited | 555.62 Million INR | 37.794% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.64% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | 75.646% |
| Par Drugs and Chemicals Limited | 58.28 Million INR | -492.974% |
| Caplin Point Laboratories Limited | 2.17 Billion INR | 84.105% |
| Shilpa Medicare Limited | 3.33 Billion INR | 89.634% |
| Valiant Laboratories Limited | 138.02 Million INR | -150.406% |
| Ajanta Pharma Limited | 30.46 Billion INR | 98.865% |
| Aarey Drugs & Pharmaceuticals Limited | 14.21 Million INR | -2331.809% |
| Granules India Limited | 10.31 Billion INR | 96.649% |
| Medicamen Biotech Limited | 335.16 Million INR | -3.123% |
| Piramal Enterprises Limited | 63.65 Billion INR | 99.457% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 98.387% |
| NATCO Pharma Limited | 10.05 Billion INR | 96.564% |
| Suven Life Sciences Limited | 109.75 Million INR | -214.928% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -648.837% |
| Strides Pharma Science Limited | 9.16 Billion INR | 96.228% |
| Indoco Remedies Limited | 12.06 Billion INR | 97.134% |
| Alpa Laboratories Limited | 127.38 Million INR | -171.34% |
| Lasa Supergenerics Limited | 291.17 Million INR | -18.703% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 88.766% |